MCRB News and Press, Seres Therapeutics Inc. From 11/05/25

2025-11-05 14:12:11 ET More on Seres Therapeutics Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026 Biggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and more See...

2025-11-05 07:14:15 ET More on Seres Therapeutics Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026 Biggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and more Seeking Alpha’s Quant Rating on Seres Therapeutics Historical...

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital...

Curaleaf Holdings Inc (CURLF) is expected to report $-0.07 for Q3 2025 Southwest Gas Holdings Inc. (DE) (SWX) is expected to report $0.09 for Q3 2025 Terreno Realty Corporation (TRNO) is expected to report $0.65 for Q3 2025 Bio-Techne Corp (TECH) is expected to report $0.36 for Q1 202...

2025-11-04 11:42:44 ET More on Seres Therapeutics Seres Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026 ...

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financia...

CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership accelerating antibacterial prod...

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place...

2025-09-23 07:50:05 ET More on Seres Therapeutics Seres Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthr...

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Company continues to enga...